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PROTEASOME INHIBITION ENHANCES THE EFFECT OF BIKDD
GENE THERAPY
Ye Sun, B.S.
Advisory Professor: Mien-Chie Hung, Ph.D.
BikDD is a phosphorylation mimic mutant form of pro-apoptotic protein Bik,
and possesses a stronger apoptosis induction capability. By constructing into a highly
amplified “VISA” (VP16-GAL4-WPRE integrated systemic amplifier) system under the
control of a cancer specific promoter, previous studies have verified the specific killing
effect of BikDD in cancer cells both in in vitro and in vivo models. C-VISA-BikDD
delivered by liposome has been approved by FDA for clinical trial in advanced pancreatic
cancer. In this study, we proposed proteasome inhibition as a combinational therapy
strategy with BikDD gene therapy to enhance the clinical benefits. Proteasome inhibition
stabilized exogenously expressed BikDD protein, and significantly enhanced the apoptosis
induction effect of BikDD. Studies on detailed mechanism for BikDD degradation revealed
that both ubiquitylation dependent and ubiquitylation independent pathways contribute to
BikDD degradation. High proteasome activity might be a potential mechanism for both
intrinsic and acquired resistance in BikDD gene therapy, and combinational therapy with
current clinically approved proteasome inhibitor would be helpful for overcoming the
resistance.
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Chapter 1 . Introduction
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1.1 Background of Apoptosis
1.1.1 The Induction and Processing Pathways for Apoptosis
Apoptosis was first described by Kerr, J.F.R. in 1972 [1], and was accepted as a
fundamental process for maintaining proper organism function by balancing death and
survival of normal cells and eliminating damaged cells. Inappropriate apoptosis would
leads to multiple diseases including immune disorders, neurodegenerative diseases and
cancers. There are two main pathways for apoptosis induction, the extrinsic pathway
initiated by ligands binding to cell membrane death receptors, and the intrinsic pathway
controlled by mitochondria signals (Figure 1.1) [2].
Extrinsic pathway of apoptosis is initiated by binding of death ligands to death
receptors on cell membrane. Most death ligands belong to Tumor Necrosis Factor (TNF)
gene superfamily, including Fas ligand, TNF, lymphotoxin α, Apo-2 ligand, and Apo-3
ligand. Their respective death receptors belong to TNF receptor gene superfamily,
including Fas, TNFR1, death receptor 3 (DR3), DR4, and DR5 [3, 4].
TNF receptor family members share the structure similarity of a cysteine-rich
extracellular domain and a homologous cytoplasmic domain called “death domain”. Death
domain is crucial in transmitting cell surface death signal to intracellular downstream
apoptosis signaling pathways. Using FasL/FasR as a model, upon binding of Fas ligand to
the Fas ligand receptor, Fas receptors form clusters through their death domain binding
with each other, and recruit the adapter protein FADD (Fas-associated Death Domain).
FADD then recruits pro-caspase-8, forming the death-inducing signaling complex (DISC).
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Caspase-8 self-cleavage after oligomerization activates itself, functions on the downstream
effector caspases and commits cell into apoptosis.

Figure 1.1 Schematic representation of apoptosis pathways.
Two main pathways of apoptosis, including extrinsic pathway and intrinsic
pathway, are as indicated. Figure is modified from Elmore, S., Apoptosis: a review of
programmed cell death. Toxicol Pathol, 2007. 35(4): p. 495-516.
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The intrinsic pathway could be initiated by multiple non-receptor stimuli that
produce intracellular signals causing mitochondrial damage. These stimuli include
radiation, toxins, hypoxia, absence or reduction of growth factors, cytokines and hormones,
etc. [4]. These stimuli lead to change in permeability of mitochondrial membrane by
forming the mitochondrial permeability transition pores. Cytochrome c releases from inside
of the mitochondria to cytoplasm and activates the caspase-dependent mitochondrial
pathway by binding and activating Apaf-1 and procaspase-9. Activated caspase-9 later
activates the downstream caspase cascade and commits cell to death.
Other pro-apoptotic proteins, including AIF, CAD and endonuclease G
permeated from inside of mitochondria, involve in last stage of apoptosis. They translocate
into nucleus and cause DNA fragmentation.
Extrinsic pathway and intrinsic pathway are not exclusive in apoptosis process.
In some cases, at least in certain cell types, extrinsic pathway and intrinsic pathway could
cross-talk with each other.
1.1.2 Bik and Other Bcl-2 Family Members in Apoptosis
Bcl-2 family proteins play pivotal controlling roles in intrinsic pathway of
apoptosis. Bcl-2 family contains up to 25 members, and is classically divided into three
main groups. One group consists of anti-apoptotic proteins, including Bcl-2, Bcl-xl, Bcl-w,
Bcl-b, MCL-1 and A1. The second group consists of pro-apoptotic proteins, including Bax,
Bak, and Bok. The third group consists of BH-3 domain only protein, including Bik, Bad,
Bid, Bim, Puma, Bmf, Noxa, and Hrk [5]. In general, pro-apoptotic proteins Bax and Bak
are important for changes in mitochondrial membrane, and their activity are inhibited by
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anti-apoptotic proteins, such as Bcl-2 and Bcl-xl under normal cell conditions. Upon
intrinsic death stimuli, BH3-only proteins bind to Bcl-2 and other anti-apoptotic proteins
and release the pro-apoptotic Bax and Bak proteins.
Activation and deactivation of Bcl-2 family proteins can be done through
multiple mechanisms, including phosphorylation, subcellular translocation, dimerization,
cleavage, etc. [6].
Bik, a 160 amino acid protein, is the first protein to link BH3 domain to cell
death activity. Bik is the founding member of BH3-only pro-apoptotic proteins [7]. The
structure of Bik is indicated in Figure 1.2. BH3 domain is crucial for its activity in inducing
apoptosis. Besides BH3 domain, the C-terminal domain (amino acid 121 to 135) is
necessary for maximal apoptosis induction activity. In adjacent to the C-terminal domain is
the trans-membrane (TM) domain. Bik could be phosphorylated on two amino acids,
Threonine 33 and Serine 35 [8]. Phosphorylation on these two amino acids could enhance
the apoptosis induction activity of Bik by increasing its binding affinity with Bcl-2 and
Bcl-xl.
The mechanism for Bik induced apoptosis is actively studied in epithelial cancer
cell lines. Multiple stimuli induce cell apoptosis through Bik by transcriptionally increasing
its mRNA level, stabilizing the protein from degradation, and activating the protein.
Stimuli influencing Bik on its mRNA level could be realized through different
transcriptional factors. According to published investigations, Bik could be activated by
Adriamycin and adenovirus through E2F1 [9], by INFγ cytokine through STAT1 [10], by
TGF-β through Smad [11], etc. Genotoxic stresses, such as γ radiation and topoisomerase
inhibitor doxorubicin, could induce Bik activation through p53 [12], but in some other
5

cases, Bik activation stimulated by genotoxic stress can be achieved through p53
independent mechanism [13]. Estrogen starvation and treatment with antiestrogens can
induce Bik activation through a p53 involved mechanism [14].

Figure 1.2 Scheme of Bik protein.
Total length for Bik protein is 160 amino acids. Bik contains one BH3 domain,
one Transmembrane (TM) domain, and one C-terminal domain. Scheme modified from
Chinnadurai, G., BIK, the founding member of the BH3-only family proteins: mechanisms
of cell death and role in cancer and pathogenic processes. Oncogene, 2008. 27 Suppl 1: p.
S20-9.

Bik mostly localizes in endoplasmic reticulum (ER), and induces apoptosis in
epithelial cancer cells through the mitochondrial caspase-9 dependent pathway [15]. Upon
stimulation, ER localized Bik induces Ca2+ release dependent on ER localized activated
Bax and Bak. The mitochondrial fission protein DRP1 gets recruited from cytosol to
mitochondria as a result of ER Ca2+ release and remodels the inner mitochondrial
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membrane cristae and leads to further cytochrome c release from mitochondria [16]. Bik
also activates Bax and Bak through binding with the anti-apoptotic proteins Bcl-2, Bcl-xl
and Mcl-1 [17].
Bik is playing an important role in multiple pathological processes. Bik has been
reported to be involved in maturation of human B lymphocytes through apoptosis selection
[18], elimination of inflammation damaged cells [10], and apoptosis induced by pathogens
[19], toxins, and virus infections [20-22]. Bik has also been well accepted as a tumor
suppressor in multiple human tumor types, including renal cell carcinomas [23], gliomas
[24], colorectal cancers [25], head and neck cancers [26], and peripheral B-cell lymphomas
[27]. Malfunction of Bik protein leads to tumor formation and development due to
blockade in tumor cell apoptosis.
1.1.3 Methods for Detection of Apoptosis
Due to important role of apoptosis in development and variety of diseases,
techniques for detection of apoptosis were developed over years. Till now, there are several
major methods to detect apoptosis.
Methods for detecting apoptosis are based on the cellular characteristics changes
during apoptosis process. These characteristics include morphological changes, DNA
fragmentation, cell membrane permeability and structure changes, cleavage of targeting
proteins by executioner caspases, and specific mediator proteins changes [28, 29]. Direct
observation of these characteristics is majorly achieved by electron microscopy, light
microscopy and fluorescence microscopy, either directly or combined with staining with
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dyes, chemicals or specific antibodies. Indirect observation is majorly achieved by DNA
gel electrophoresis, Western Blot detecting protein, ELISA, and flow cytometry.
Apoptosis was first observed due to the cell morphologies changes by electron
microscopy [1], thus electron microscopy is considered as the golden standard test to
identify apoptosis. These morphologies changes include shrinkage of the cell, nuclear
condensation and break up, reduced attachment from the surrounded tissues and cells,
plasma membrane separation and formation of separate membrane, apoptotic bodies
formation, etc. [30]. Electron microscopy is highly sensitive and specific in detecting
apoptosis, and can be combined with other staining assays to further strengthen its effect.
DNA fragmentation, another representative characteristic during apoptosis, can
be detected by multiple methods [30]. TUNEL (the terminal deoxynucleotidyl transferasedUTP nick end labeling) assay is one of the widely used methods for detection of DNA
fragmentation. The mechanism for TUNEL assay is terminal deoxynuclotidyl transferase
binds specifically to 3’-OH ends of fragmented DNA and incorporate dUTP at the site of
DNA breaks. By linking of detectable tags, such as biotin and fluorescein, with dUTP,
DNA fragmentation can be then observed by microscopy, immunohistochemistry or flow
cytometry detection [31, 32]. Gel electrophoresis is another widely used assay for detecting
DNA fragmentation. Due to the fragmentation of DNA is done by endonucleases
specifically to 180 to 200 base pairs, DNA separated by gel electrophoresis is supposed to
show the hallmarked “laddering” pattern.
Based on the changes of cell membrane permeability, apoptotic cells can be
stained by dyes such as Trypan blue [33], its DNA can be bound by PI (propidium iodide)
[34, 35] while live cells not undergoing apoptosis can not.
8

During apoptosis, phosphatidylserine (PS) would translocate from the inner cell
membrane to the outer cell membrane, and allows for phagocytic cells recognition and
elimination [36, 37]. Based on the phenomenon, Annexin V, which has a specific and
strong binding affinity with PS, is used to detect cell apoptosis. Annexin V can be
conjugated with detectable tags, and its signal is usually tested by microscopy or flow
cytometry.
Another representative character for apoptosis is activation of caspases and the
cleavage of their targeting proteins. One of these targeted protein is the DNA-dependent
protein kinase and poly(ADP-ribose) polymerase (PARP) [38]. PARP normally binds to
specific DNA strand breaks and function to repair the DNA damage. Upon apoptosis
induction, caspase 3 and caspase 7 cleave and inactivate this 113kD full length protein into
two 89kD and 24kD fragments. Antibody detection of PARP cleavage is considered to be
one of the widely used methods for detection of apoptosis [39].
Here are multiple other methods for detecting apoptosis which are not discussed
in this introduction. Such methods include detection of caspases proteins, mitochondrial
potential, cytochrome c, Bcl-2 family proteins, etc. [40-45].

1.2 Background of Protein Degradation
Proteins in live cells are under precisely dynamic control. Proteins have different
half-lives, ranging from seconds to days, depending on their functions, quality, and the
status of the cells. Protein turn-over is processed in a specific, complicated, spatially and
temporally controlled mechanism. Degradation of unwanted proteins plays a pivotal role in
maintaining normal cell differentiation, proliferation, apoptosis, and adaptation to changing
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environment, and malfunction in this process could lead to multiple diseases including
tumorigenesis, neurodegenerative diseases, etc. In eukaryotic systems, the major machinery
for degrading mis-folded, aged and damaged proteins are proteasome and lysosome [46,
47].
1.2.1 Proteasome Complex Structure
The core structure of proteasome system is 20S proteasome which is 700 kD and
composed of 2 pairs of stacked, heptameric rings. The two inner rings are identical and
each of them is composed of 7 different but related β-units. 3 β-units (β1, β2, and β5)
contain proteolytic sites, thus a 20S proteasome contains total 6 proteolytic sites in its core
compartment. These proteolytic sites are responsible for hydrolyzing peptide bond between
amino acids, with different proteolytic activities. The two outer rings are also identical and
each of them is composed of 7 different but related α-units. The outer rings are responsible
for association with different regulatory complexes and translocation of substrates into the
core proteolytic chamber [48-54].
The 20S proteasome can associate with different regulatory complexes. There
are three types of activators and two inhibitory proteins in reports. The two inhibitory
proteins are proteasome inhibitor 31 (PI31), functions through inhibiting the binding
between 20S proteasome and activators, and Pr39, functions through reducing the
degradation of specific protein by binding to the α7 unit [55-58].
19S regulatory complex is the most studied activator. It contains two catalytic
activities, ATP hydrolysis and deubiquitylize activity, and is considered to be necessary for
processing of the ubiquitylated proteins degradation. 19S proteasome is divided into two
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compartments structurally, the base and the lid [59]. The base includes 6 ATPases, which
are regulatory particle triple A protein (Rpt) 1-6, and four regulatory particle non-ATPase
(Rpn) 1, 2, 10, and 13, which function either as the organizing units or ubiquitin receptors.
The ATPase ring is responsible for final unfolding the substrate proteins and their
translocation into the core proteolytic chamber as well as controlling the gating of 20S
proteasome orifice. The lid functions for recognizing ubiquitylated proteins and their
deubiquitylation, and is composed of the deubiquitylating enzyme Rpn11, its binding
partner Rpn8 which does not have a catalytic activity, and seven scaffolding proteins.
In addition to the regulatory functions provided by 19S proteasome itself, a
variety of proteins can bind to 19S proteasome to regulate protein degradation. Some of
these proteins, such as Radiation Sensitive 23 (Rad23), Dominant Suppressor of Kar2
(Dsk2), and DNA Damage-inducible 1 (Ddi1) function as the alternative ubiquitin
receptors through their ubiquitin-like and ubiquitin-associated domains.
Proteasome activator 28 (PA28) contains two types, PA28αβ and PA28γ. They
are the 11S activating complex. Another proteasome activator is PA200. PA200 and 11S
activator complex can facilitate protein degradation without ubiquitin recognition and ATP
hydrolysis, but their detailed function and mechanism are not clearly studied [55, 60-72].
20S proteasome can associate with different activators on either end or both
ends. 20S proteasome associated with one or two 19S regulatory complexes composes the
well-known 26S proteasome, which has been identified at near atomic resolution for the
crystal structure and is mostly referenced in protein degradation studies [73-80].
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1.2.2 Ubiquitylation Dependent Protein Degradation
The best studied pathway for protein degradation is the ubiquitylation dependent
degradation pathway. Polyubiquitylated proteins could be recognized by 26S proteasome
through its ubiquitin recognition subunits, deubiquitylated and unfolded through subunits
with respective activities. Then unfolded substrate protein gets translocated into the 20S
proteasome core catalytic chamber, and is degraded into small peptides and single amino
acid after the peptide bond between amino acids get hydrolyzed [81-83].
In most cases of protein degradation, polyubiquitylation chain on the substrate
proteins serves as the recognition tag for proteasome complex. Ubiquitin is most often
conjugated on lysine sites of the substrate protein through an isopeptide bond between the
ε-amino group of the lysine and the C-terminal carboxy group of the ubiquitin.
Polyubiquitin chain could be elongated through conjugating latter ubiquitin onto the
previous ubiquitin by formation of isopeptide bond between lysine of the previous
ubiquitin and C-terminal of the latter ubiquitin. Ubiquitin has 7 lysine amino acids in total,
and conjugation through different sites might exert different function. K48 conjugated
polyubiquitin chain is the most widely accepted tag for protein degradation through
proteasome [84], monoubiquitin on K11 and K63 have also been reported involved in
protein degradation [85-89].
Besides the most classical lysine site, ubiquitylation has been reported to occur
on N-terminal of the protein through formation of a regular peptide bond [90-92], and on
cysteines, serines, and threonines through formation of thioester and hydroxyester linkage
[93-95].
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Ubiquitylation is achieved through an enzymatic cascade. Ubiquitin first needs
to be activated by the ubiquitin activating enzyme (E1) through an ATP-dependent process.
This step is achieved through formation of a thioester bound between ubiquitin carboxy
terminus and a cysteine on E1. Up to date, eight E1 have been identified.
The second step is to transfer the activated ubiquitin onto the ubiquitinconjugating enzyme (E2) through forming a thioester bound [96]. There are over 30 E2s
identified up to date, and they perform certain specificity for substrate ubiquitylation.
Another important component for ubiquitylation is the ubiquitin ligase (E3).
There are thousands of E3s in cells with high specificity to recognize and degrade substrate
protein. E3 could be divided into two major groups, the HECT domain group and the Ring
finger domain group. The Ring finger domain E3 functions by bringing ubiquitin-E2 and
the substrate together, thus allow the transfer of ubiquitin from E2 to the substrate [97100]. Ubiquitin would be transferred to HECT domain E3s first before it is finally
conjugated onto the substrate.
1.2.3 Ubiquitylation Independent Protein Degradation
Although in most cases proteins degraded by proteasome are through the
ubiquitylation pathway, here are some exceptions. Some studies have reported the
existence of ubiquitylation independent proteasome degradation. The mechanism for
ubiquitylation independent proteasome degradation is not totally clear, but some proteins
undergo this pathway have been detailed studied. Such proteins include Rnp4, thymidylate
synthase, ornithine decarboxylase, p21, p53, c-Fos, Fra-1, HIF-1, Rb and so on, and some
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of these proteins could undergo both ubiquitylation dependent and independent pathways
for degradation [101-111].
Degradation through ubiquitylation independent pathway can be achieved by the
protein intrinsically unstructured region, or exposure of the hydrophobic region with the
help from other proteins. In general, aged proteins, misfolded proteins, and highly oxidized
proteins are the major targets for ubiquitylation independent proteasome degradation [112116].

1.3 Bik and BikDD in Cancer
Bik functions as a fundamental pro-apoptotic protein, and its dys-regulation
might lead to multiple diseases, including cancer. Bik has been reported as a tumor
suppressor in specific tissues, and its expression could be reduced on transcription level
due to epigenetic silencing or chromosome deletion or mutation in certain types of cancers.
Some studies also showed that Bik protein was actively targeted and degraded by
proteasome system in some cancer cells, although the mRNA of Bik was constitutively
transcribed [20, 117-123].
Due to the tumor suppressor role of Bik, multiple groups have put efforts to
rescue its expression to induce cancer cell apoptosis. These strategies include treatment of
DNMT1 (DNA Methyltransferase 1) inhibitors [124], histone deacetylase (HDAC)
inhibitors to rescue Bik on the mRNA transcription level [125, 126], and proteasome
inhibitor to stabilize Bik on the protein level [119, 121, 123]. Overexpression of Bik by
adenovirus infection has been shown with tumor suppression effect on chemoresistant
cancer cells [127].
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As mentioned before, phosphorylation on T33 and S35 on Bik provides stronger
apoptosis induction effect. Our lab previously made a mutant form of Bik by mutating
these two amino acids into aspartic acid to mimic the phosphorylation status and named it
BikDD. BikDD indeed gives better killing effect in cancer cells compared with wild type
Bik, provides stronger ability in apoptosis induction both in vitro and in vivo [8, 128, 129].
BikDD is designed to be delivered into patients by liposome. To achieve the
specific expression in target tumor cells, we constructed a versatile expression VISA
(VP16-GAL4-WPRE integrated systemic amplifier) system (Figure 1.3) [130]. Our VISA
expression vector is modified from the two-step transcriptional amplification (TSTA)
system [131] which involves two steps in expression of the tissue specific gene. The first
step is activation of expression of GAL4-VP16 fusion protein under the control of a tissue
specific promoter which is usually weak. Then, the GAL4-VP16 fusion protein binds to
GAL4 response elements located upstream of the BikDD gene and activates its expression
under the GAL4 responsive promoter G5E4T [132-140]. We also added WPRE
(Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element) into the TSTA
system. Addition of the WPRE sequence provides more active expression of the target
BikDD gene and prolongs duration of the gene expression (Figure 1.3) [130, 141, 142].

15

Figure 1.3 Scheme for VISA-BikDD construct.
GAL4-VP2 is under the control of cancer specific promoter, and translated into
GAL4 protein fused with two copies of VP16. Red boxes stand for GAL4 response
element. Binding of GAL4-VP16 protein with the response element turns on the minimal
promoter G5E4T indicated by the yellow box. WPRE element is placed on the 5’ end of
BikDD gene for its posttranscriptional regulation.

By inserting CCKAR pancreatic cancer specific promoter into the VISA-BikDD
vector, we made the C-VISA-BikDD plasmid. Delivered by liposome, the C-VISA-BikDD
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can be expressed and induce apoptosis specifically in pancreatic cancer cells, and prolong
mouse survival in orthotopic and xenograft model with minimal toxicity [130].
By changing the cancer specific promoter, VISA-BikDD system has also been
applied to breast cancer (with Claudin-4 promoter or hTERT promoter) [143, 144], lung
cancer (with Survivin promoter) [145-147], and hepatocellular carcinoma (with αfetoprotein promoter) [148], and approved to be effective in eliminating specific cancer
cells and prolong long-term survival in these cancer types.
In 2009, C-VISA-BikDD: liposome in advanced pancreatic cancer has been
approved by FDA for phase I clinical trial to assess the safety and tolerability of the CVISA-BikDD nanoparticle in patients. This trial is expected to begin recruiting patients in
July 2014 and finish in 2016.

1.4 Resistance in Cancer Therapy
An inevitable problem for cancer therapy is resistance, which is one of the major
reasons for failure of treatment and poor patient survival. Resistance might occur prior to
cancer treatment (intrinsic resistance) or as a result of treatment (acquired resistance) [149,
150].
Intrinsic resistance might be contributed by the heterogeneity of cancer
population. There might be a small population of cancer cells possess some characteristics
that hard to be targeted and killed by the certain therapy method. While the therapy
eliminating most cancer cells that are sensitive to treatment, these small population of
resistance cancer cells could not be removed and would lead to the final recurrence.
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Acquired resistance might occur through multiple mechanisms. These
mechanism include activation of compensatory signaling pathways, mutations and
amplification of drug target genes, alteration in drug metabolism and transportation, etc
[151-159]. And these alterations come from accumulation of genetic and epigenetic
changes.
Due to the widely occurrence of cancer treatment resistance, understanding the
underlying mechanism for resistance is important to increase treatment effect and improve
patient survival through providing information on prognostic markers to predict patient
response, and combination treatment to overcome resistance.
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Chapter 2 . Materials and Methods
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2.1 Materials
2.1.1 Cell Lines
MDA-MB-231 is a triple negative breast cancer cell line, derived from
metastatic site, and is widely used as a model for breast cancer study. AsPC-1 and MIA
PaCa-2 are pancreatic cancer cell lines. 293T is a human embryotic kidney cell line
containing SV40 T-antigen and is a highly transfectable cell line. These cell lines were
purchased from ATCC (American Type Culture Collection). L3.6pL cell line is a
pancreatic cancer cell line, and was kindly provided by Dr. Chiao Paul, Department of
Molecular and Cellular Oncology Department, University of Texas MD Anderson Cancer
Center. These cell lines were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM)/Ham’s F-12 1:1 Mixture with 10% FBS and antibiotics penicillin-streptomycin
and antimycotic. Stable cell lines were selected and maintained with either 1µg/mL
puromycin or 1mg/mL neomycin according to the resistance provided by different plasmids
infected. Cells were cultured in incubator at 37ºC in 95% air and 5% CO2. Cells were
passaged every 2-4 days according to the growing rate to prevent over-confluency. When
passaging, cells were washed with 37ºC PBS once, incubated with Trypsin (0.25% w/v)EDTA (0.53nM) until they rounded and lifted off the plate. Trypsin-EDTA was then
neutralized by DMEM/ Ham’s F-12 with 10% FBS, and cells were collected for
centrifugation at 1000 rpm for 3-5min. Cells were then split at 1:6 to 1:8 for subculture.
Stocked cells were re-suspended in FBS containing 5%-10% DMSO, freezed in -80ºC for
24h, then transferred into liquid nitrogen tank for long term stock.
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2.1.2 Plasmids
BikDD was constructed by site-directed mutagenesis on Threonine 33 and
Serine 35, both mutated into Aspartic acid from Bik as indicated by previous publications
[130]. BikDD segment with Flag segment fused on the 5’ end was inserted into CD510B1_pCDH-CMV-MCS-EF1-Puromycin vector by restriction sites EcoRI and BamHI. Lysine
mutation on BikDD was constructed by site-directed mutagenesis on site 115, site 160, or
both into Arginine. These gene segments were constructed into CD511B-1_pCDH-CMVMCS-EF1-copGFP vector by restriction sites EcoRI and NotI.
2.1.3 RNA Interference
siRNA targeting AMFR and Bik were purchased from Sigma-Aldrich (St. Louis,
MO). P6592 MSCV-IP N-HAonly WWP2 construct was purchased from Addgene.
Lentiviral packaging system, pCMV-dR8.2 dvpr (#8455) and pCMV-VSVG (#8454), were
purchased from Addgene. Lentiviral shRNA constructs targeting gene AMFR were
purchased from MISSIONTM TRC-Hs (human) shRNA Library (Sigma-Aldrich, St. Louis,
MO). Lentiviral shRNA targeting gene HECTD1 and HUWE1 were purchased from GIPZ
lentiviral shRNA library (shRNA and OFRome Core, MD Anderson Cancer Center,
Houston, TX), GIPZ lentiviral empty vector shRNA was purchased and used as negative
control. The oligo sequence for shRNAs are listed below.
pLKO.1 Scrambled Control (#1864, Addgene):
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAG
G;
AMFR shRNA (TRCN0000003374):
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CCGGCATGAGGTGCAACGTCGAATTCTCGAGAATTCGACGTTGCACC
TCATGTTTTT (Targeting CDS of AMFR);
AMFR shRNA (TRCN0000003375):
CCGGCCTCGCTTAAACCAACACAATCTCGAGATTGTGTTGGTTTAAGC
GAGGTTTTT (Targeting CDS of AMFR);
HECTD1 shRNA (V2LHS_149725):
TTAAACCCATCTCTAAAGG (Mature antisense targeting CDS of HECTD1);
HECTD1 shRNA (V2LHS_149726):
TTAAAGTCTCTGATGTCTC (Mature antisense targeting 3’ UTR of
HECTD1);
HUWE1 shRNA (V3LHS_353155):
ATCTGAAGGACATCTACCA (Mature antisense targeting CDS of HUWE1);
HUWE1 shRNA (V2LHS_110969):
ACTTGAAGTAGCTGAGGTG (Mature antisense targeting CDS of HUWE1).
2.1.4 Antibodies
Antibodies used in this study were listed in Table 2.1. Antibodies purchased
from Cell Signaling Technology Inc. (Danvers, MA) include Bik (4592S), PARP (9542S),
and AMFR(9590S). Antibodies purchased from Sigma-Aldrich (St. Louis, MO) include αTubulin (T5168), β-Actin (A2066), and Flag (F3165). Antibodies purchased from Bethyl
Laboratories Inc. (Montgomery, TX) include HECTD1 (A302-908A), HUWE1 (A300-
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486A), and WWP2 (A302-935A). Antibody purchased from Abcam (Cambridge, ENG)
includes Lamin B (Ab16048).
Antibodies and Dilutions
Antibody Target

Company
Cell

Bik

Signaling

PARP

Cell
Signaling

Catalog Number

Dilution

Molecular Weight (kDa)

4592S

1:1000

20

9542S

1:1000

Full length 113
Cleaved 89

α-Tubulin

Sigma

T5168

1:1000

50

β-Actin

Sigma

A2066

1:1000

42

LaminB

Abcam

Ab16048

1:1000

67

9590S

1:1000

78

AMFR

Cell
Signaling

HECTD1

Bethyl

A302-908A

1:1000

290

HUWE1

Bethyl

A300-486A

1:1000

480

WWP2

Bethyl

A302-935A

1:1000

99

Flag

Sigma

F3165

1:1000

1

Table 2.1 List of antibodies used and detailed information

2.1.5 Reagents
The following reagents were purchased from Thermo Fisher Scientific, Inc.
(Waltham, MA). SuperScript III first-strand synthesis supermix (18080-400);
Lipofectamine 2000 tansfection reagent (11668-019); dNTP Mix (18427-013); Puromycin
(ant-pr-5); TRIzol reagent (15596018); Luria Broth base (12795-084); Penicillin-
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Streptomycin (15140-163); Trypsin-EDTA (15400-054); Antibiotic-Antimycotic (15240112); Opti-MEM I reduced-serum medium (31985-070); BCA protein assay kit (PI23227);
Sodium chloride (S271-3); Methanol (A433s-20); Glycine (BP381-5); Isopropanol
(BP2618-4); Acetic acid (A381-212); Tris base (BP1525); Dimethyl sulfoxide (DMSO)
(BP231-1); Polybrene infection/transfection reagent (NC9515805); Hydrochloric acid
(HCl) (A481-212); HEPES (BP310-500); Glacial acetic acid (A38S212); G418
(MT61234RG); Acrylamide (flake-like crustal) (O1065500); Potassium chloride (KCl)
(BP366-500); Glycerol, 99.5% (AC327255000); Ethanol (2801).
The following reagents were purchased from Sigma-Aldrich Co. LLC. (St.
Louis, MO). Cycloheximide solution microbial (C4859); TWEEN 20 (P1379); Sodium
orthovanadate (Na3VO4) (S6508); Aprotinin from bovine lung saline solution (A6279); LB
agar (L2897); Kanamycin (K4000); Ampicillin sodium salt (A0166); Agarose molecular
biology reagent (A9539); Acrylamide for electrophoresis (A3553); Sodium phosphate
dibasic (Na2HPO4) (S0876); Dulbecco's Modified Eagle's Medium (DMEM) nutrient
mixture F-12 HAM (D8900); Sodium dodecyl sulfate (SDS) (L5750);
Ethylenediaminetetraacetic acid (EDTA) disodium salt dehydrate (E5134); Sodium
deoxycholate (D6750); Ammonium persulfate (A9164); Potassium phosphate monobasic
(KH2PO4) (P-5379); Propidium iodide (PI) (P4170); Sodium fluoride (NaF) (S1504);
Phenylmethylsulfonyl fluoride (PMSF) (P7626); Boric acid for molecular biology (B6768);
Bromophenol blue, sodium salt (B-5525); Ethylene glycol tetraacetic acid (EGTA) (E4378).
The following reagents were purchased from Atlanta Biologicals, Inc. (Norcross,
GA). Fetal bovine serum-optima (S12450).
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The following reagents were purchased from MP Biomedicals, LLC. (Santa Ana,
California). Tetramethylethylenediamine (TEMED) (04805614).
The following reagents were purchased from LabScientifics Inc. (Highlands,
NJ). Non-fat dry milk (M0841).
The following reagents were purchased from Gemini Bio-Products (West
Sacramento, CA). BSA, standard grade (700100P).
The following reagents were purchased from Bio-Rad Laboratories, Inc.
(Hercules, CA). iQ SYBR green supermix (1708880); Clarity western ECL substrate
(1705601); Precision plus prorein dual color standards (1610394).
The following reagents were purchased from QIAGEN (Venlo, Limburg).
QIAGEN plasmid maxi kit (12165); QIAprep spin miniprep kit (27106).
The following reagents were purchased from Agilent Technologies (Santa
Clara, CA). Pfu Turbo DNA polymerase (600250).
The following reagents were purchased from Promega Co. (Madison, WI). T4
DNA ligase (M1801).
The following reagents were purchased from Hoffmann-La Roche Inc. (Bazel).
Protein A agarose (11 134 515 001); Protein G agarose (11 243 233 001); Taq DNA
polymerase (11 435 094 001L); Dithiothreitol (DTT) (03 117 006 001).
The following reagents were purchased from Selleck Chemicals (Houston, TX).
MG132 (MG132).
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The following reagents were purchased from New England Biolabs Inc.
(Ipswich, MA). EcoR I-HF (R3101s); Not I – HF (R3189s); 1kb DNA Ladder (N3232L);
BamH I (R0136s).
The following reagents were purchased from BD Pharmingen Inc. (San Diego,
California). APC-Annexin V (550474); Annexin V Binding Buffer (556454).
The following reagent was purchased from LC Laboratories (Woburn, MA).
Bortezomib (B-1408).
2.1.6 Equipment
The following equipment was used in our study.
Olympus IX71 inverted microscope (Olympus Corporation of the Americas,
Shinjuku, Tokyo); BD FACSCanto II (BD Biosciences, San Jose, CA); Rocker II 260350
Platform Rocker (Boekel Industries Inc., Feasterville-Trevose, PA); Kenmore Appliances
frostless freezer 20 (Sears Brands, LLC, Chicago, IL); Corning PC-320 PC320 Hot Plate
Stirrer (Corning Inc., Corning, NV); Bio-rocker model IIOA (Denville Scientific Inc.,
South Plainfield, NJ); Revco PLUS -86°C Freezers (Thermo Fisher Scientific Inc.,
Waltham, MA); UB-10 UltraBASIC pH/mV Meter (Denver Instrument, Bohemia, NY); T100 Thermal Cycler (Bio-Rad Laboratories, Inc., Hercules, CA); AutoFlow NU-8500
Water Jacket CO2 Incubator (Nuaire, Plymouth, MN); NanoDrop 2000 UV-Vis
Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA); Alpha Innotech
FluorChem 8900 imaging system (Proteinsimple, Santa Clara, CA); Lab Companion IS971 Floor Model Incubated Shaker (JEIO Tech Co. LTD., Korea); Electronic Balance Prec
ML1501E (Mettler-Toledo International Inc., Columbus, OH); Mini Protean 3
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Electrophoresis Cell 525BR (Bio-Rad Laboratories, Inc., Hercules, CA); Mini Trans-Blot
Electrophoretic Transfer Cell #170-3930 (Bio-Rad Laboratories, Inc., Hercules, CA);
EVOS FL Cell Imaging System Revolutionizing fluorescent microscopy (Life
technologies, Carlsbad, CA); Precision Dual-Chamber Water Bath 188, Part Number: 2851
(Thermo Fisher Scientific Inc., Waltham, MA); MaxQ 2000 Digital Shaker, Part Number:
SHEK2000 (Thermo Fisher Scientific Inc., Waltham, MA); VORTEX-GENIE 2 Vortex
Mixer (Scientific Industries, Inc., Bohemia, NY); PMC-060 CAPSULEFUGE 220V 6300
R/MIN centrifuge (TOMY Digital Biology, Co., LTD,Japan); Power Pac 3000
Electrophoresis Power Supply (Bio-Rad Laboratories, Inc., Hercules, CA); Microcentrifuge
5415R (Eppendorf AG, Hamburg, Germany); Microcentrifuge 5810R (Eppendorf AG,
Hamburg, Germany); Amaxa Nucleofector I (Lonza Group Ltd., Basel, Switzerland).

2.2 Methods
2.2.1 Transfection
Transfection in cancer cells was done with Lipofectamine 2000 following the
manufacture’s instruction. Cancer cells were seeding in 6-well plate, attached and grew
overnight. Before transfection, cells were changed into 1ml Opti-MEM I reduced-serum
medium for 30min. Plasmid DNA was added into 100 µl Opti-MEM I reduced-serum
medium, mixed by pipetting. Lipofectamine was added into 100 µl Opti-MEM I reducedserum medium, mixed by pipetting as well. The ratio of DNA and Lipofectamine was 1µg:
1µl. Lipofectamine medium was then added into the DNA medium after 5min, and mixed
by gently pipetting. The mixed liquid was then incubated for 30min, then added onto the
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cell. Opti-MEM I reduced-serum medium was changed into normal culture DMEM/ Ham’s
F-12 medium with 10% FBS after 4h.
2.2.2 Establishment of Stable Cells
Stable cell lines were established by lenti-virus infection. Virus was packaged in
293T cells. The procedure for 293T cell transfection was similar to transfection in cancer
cell lines. . 293T cells were seeding in 10cm cell culture dish, attached and grew overnight.
Before transfection, cells were changed into 4ml Opti-MEM I reduced-serum medium for
30min. Plasmid DNA was added into 500 µl Opti-MEM I reduced-serum medium, mixed
by vortex. Lipofectamine was added into 500 µl Opti-MEM I reduced-serum medium,
mixed by vortex as well. The ratio of DNA and Lipofectamine was 1µg: 1µl. DNA medium
was then added into the Lipofectamine medium after 15min, and mixed by immediate
vortex for 6 to 8 times. The mixed liquid was then incubated for 30min in room
temperature, then added onto the cell. Opti-MEM I reduced-serum medium was changed
into normal culture DMEM/ Ham’s F-12 medium with 10% FBS after 4h. Cell culture
supernatant containing lenti-virus was collected and filtered by 0.45µm polyvinylidene
fluoride (PVDF) membrane filter after 48h to 60h.
Cancer cells for infection were seeded and grew overnight. Then lenti-virus
containing medium was diluted by DMEM/ Ham’s F-12 fresh medium containing 10%
FBS with 10µg/ml polybrene to neutralize the charge repulsion between viruses and cell
surface. 24h after infection, cells were changed into normal culture medium for another
24h, then cultured in medium with selection antibiotics until cells were stable.
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2.2.3 siRNA Transfection
siRNA transfection was done by electroporation by Amaxa Nucleofector I (Lonza Group
Ltd., Basel, Switzerland). Cancer cells for electroporation was trypsinized, collected,
centrifugated, resuspended and counted. 0.5-2×106 cells were taken into a new tube,
centrifugated and resuspended with 110 µl electroporation buffer (120mM KCl, 0.15mM
CaCl2, 10mM Na2HPO4, 6mM Glucose, 25mM HEPES, 2mM EGTA, 5mM MgCl2, pH
7.6). siRNA was prepared in DEPC-treated water into 10µM concentration. 10µl siRNA
was added into the cancer cells, and the cells were transferred into the electroporation
cuvette, and program B-018 was runned for electroporation. Then cells were taken out of
the cuvette and seeded into culture plates. Properties of the transfected cells were tested
after 48-96h.
2.2.4 Western Blot
Cells were collected and lysed by lysis buffer (3.3% SDS, 1.7M Urea). Cell
sample protein quantification was detected by BCA kit following manufacture’s
instruction, diluted with 5×SDS loading dye buffer (10% SDS, 10mM DTT, 20% Glycerol,
0.2M Tril-HCl, 0.05% Bromophenoblue, pH 6.8), and loaded for separation by
polyacrylamide gel electrophoresis (PAGE). According to the targeted protein molecular
weight, 8%-12% SDS-polyacrylamide gels were used. Electrophoresis was done in
1×running buffer (25mM Tris, 190mM Glycine, 0.1% SDS, pH8.3) under 100V until the
lower blue indicator dye got to the bottom of the gel. Protein sample were then transferred
from SDS-PAGE gel onto PVDF membrane in 1×Transfer buffer (25mM Tris, 192mM
Glycine, 20% Methanol) at 100V for 80-100min with a Mini-Gel Transfer apparatus
following manufacture’s instruction.
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PVDF Membrane was blocked by 5% non-fat milk in Tris-buffered saline (TBS)
(50mM Tris-HCl, 150mM NaCl, pH7.6) to prevent non-specific binding for 30-60min. The
membrane was then incubated with primary antibody at 4ºC for overnight. TBST (Trisbuffered saline, 0.1% Tween-20) was used for washing the membrane for 10min, 3 times.
Secondary antibody was then diluted in 5% non-fat milk TBS buffer for membrane
incubation for 60-90min. TBST was used for washing the membrane for 10min, 3 times.
Membrane was then incubated in ECL solution for 1-2min, then developed with an X-ray
film with exposure time ranging from 1s to 10min.
2.2.5 Flow Cytometry
Cells were deattached by trypsin-EDTA treatment, and collected into
centrifugation tubes including the floating cells. Cells were then washed twice with cold
phosphate-buffered saline (PBS) (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM
KH2PO4, pH 7.4). Resuspend cells in 1×binding buffer (10mM Hepes, 140mM NaCl,
2.5mM CaCl2, pH 7.4) at a concentration of 1×106 cells/ml. Then 100µl solution was
transferred into a 5ml flow cytometry tube. 5µl APC-Annexin V was added into the
solution and incubated for 15min at room temperature in the dark. 400µl binding buffer and
1µl PI was added into the solution before analyzed by flow cytrometry.
2.2.6 Mass Spectrum
MDA-MB-231 breast cancer cell line was infected by lentivirus for stably
expression of Flag-BikDD. Cells were treated with DMSO or 10µM MG132 for 8h before
collection by RIPA (Radio-Immunoprecipitation Assay) buffer (50mM Tris-HCl, 150mM
NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1mM EDTA, 1mM PMSF, 1µg/ml
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Aprotinin, 1mM Na3VO4, 1mM NaF, pH 7.4). Cells were lysed, and incubated with mouse
derived Flag antibody overnight. Then protein G beads were added to immunoprecipitate
Flag-BikDD and its binding proteins by recognizing Flag antibody. These proteins were
then eluted by Flag peptide, analyzed by gel electrophoresis and Western blot. All the
proteins were analyzed by nanoelectrospray mass spectrometry which was performed using
an Ultimate capillary LC system (LC Packings, Amsterdam, The Netherlands) coupled to a
QSTARXL quadrupole-time of flight (Q-TOF) mass spectrometer (Applied
Biosystem/MDS Sciex, Foster City, CA) for protein ID identification.
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Chapter 3 . Results
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3.1 BikDD is Degraded through Proteasome
The C-VISA-BikDD liposome gene therapy contains two major components, the
liposome delivery system and the C-VISA-BikDD plasmid. In our study, we aimed at
enhancing the effect of gene therapy by focusing on the core effector protein, BikDD.
Pro-apoptotic protein Bik has been reported to be degraded through proteasome
degradation pathway, and its accumulation is important in proteasome inhibitor induced
cell death [119, 123]. To test whether BikDD has the similar character with Bik, we
transfected BikDD plasmid into MIA PaCa-2 cells, and tested its expression level with or
without the treatment of the specific proteasome inhibitor MG132 at 10µM for 8 hours.
Western blot result showed clearly that endogenous Bik expression level in MIA PaCa-2
cell was very low, and MG132 treatment did not have a significant effect in accumulating
its protein level. Compared with that, MIA PaCa-2 transfected with BikDD plasmid
showed a detectable level of BikDD protein, and treatment with MG132 lead to a
significant increase in BikDD protein expression (Figure 3.1).
Other cancer cell lines, including MDA-MB-231, and L3.6pL, were hard to be
transfected, thus tested with lentivirus infection. Western blots showed similar results.
Endogenous Bik expression in these cancer cell lines were low and hard to be detected.
Proteasome inhibitor MG132 treatment significantly increased the level of BikDD protein
in transfected samples (Figure 3.1).
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Figure 3.1 Proteasom inhibitor MG132 stabilizes BikDD expression in different cell lines.
A. MIA PaCa-2 cells was transfected with vector control construct or BikDD
construct by Lipofectamine 2000 for 24h, followed by DMSO treatment or 10µM MG132
treatment for 8h as marked; B. Same experiments as A were done in MDA-MB-231 cancer
cells. Due to poor efficacy of liposome transfection, vector control or BikDD lentivirus was
infected into MDA-MB-231 cells for 24h followed by DMSO or 10µM MG132 treatment
instead of Lipofectamine transfection. C. Same experiments as B were done in L3.6pL
cancer cell line. Cleaved PARP was used as a marker for cell apoptosis.
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3.2 Combination of BikDD and Proteasome Inhibition Provided Better
Killing Effect in Cancer Cells
BikDD protein can be stabilized by proteasome inhibitor indicated exogenously
expressed BikDD protein from transfected plasmid can be degraded through proteasome
pathway, leading to a reduced effect in inducing cell apoptosis.
To test if proteasome inhibition can facilitate the killing effect of BikDD,
apoptosis level of transfected cells was measured by PARP cleavage. Along with the
accumulation of BikDD protein level in infected MDA-MB-231 cells treated with MG132,
level of cleaved PARP also increased indicating an increased apoptosis level. The same
result was repeated in pancreatic cancer cell lines L3.6pL (Figure 3.1).
Bortezomib (Velcade) is the first proteasome inhibitor tested in human, and has
been approved by FDA for clinical use as an anti-cancer drug in multiple myeloma and
mantle cell lymphoma. It functions by specific binding to the catalytic site in the 26S
proteasome with high affinity. Bortezomib was also used in the study to test if it could
provide the same effect as MG132 in accumulating BikDD protein and enhancing cell
apoptosis. Western blot results showed Bortezomib treatment provided an obvious effect in
stabilizing BikDD protein and enhance cancer cell apoptosis in MDA-MB-231, AsPC-1
and L3.6pL cell lines indicating by an increased PARP cleavage (Figure 3.2).
The effect of combining proteasome inhibition and BikDD was also tested by
measuring the cell apoptosis by Flow Cytometry. MDA-MB-231 cells were infected with
vector control or BikDD lentivirus for 24h, and then each group of cells were treated with
ethanol-control or Bortezomib at 50nM for 16h. Cells were then collected, stained with
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Figure 3.2 Clinical approved proteasom inhibitor Bortezomib stabilizes BikDD expression
and enhance apoptosis in different cell lines.
A. MIA PaCa-2 cells were transfected with vector control construct or BikDD
construct by Lipofectamine 2000 for 24h, followed by ethanol control, 200nM Bortezomib,
400nM Bortezomib treatment for 6h respectively as marked; B. Same experiments as A
were done in MDA-MB-231 cancer cells. Due to poor efficacy of liposome transfection,
vector control or BikDD lentivirus was infected into MDA-MB-231 cells for 24h followed
by ethanol and Bortezomib treatment instead of Lipofectamine transfection. C. L3.6pL
cells were infected with vector control or BikDD lentivirus followed by ethanol control or
200nM Bortezomib treatment for 6h as marked. Cleaved PARP was used as a marker for
cell apoptosis.
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APC-Annexin V and PI, and analyzed by Flow Cytometry (Figure 3.3). In the control
group which infected with vector control lentivirus, cell apoptosis percentage increased by
Bortezomib treatment was detectable, but not significant. Lentivirus infection leaded to low
expression of BikDD expression in MDA-MB-231 cells. When combined with Bortezomib
treatment, percentage of cell undergo apoptosis increased statistically significantly. Similar
experiment was carried out in MIA PaCa-2 cell line. MIA PaCa-2 cells were infected with
vector control or BikDD lentivirus for 24h, and each group of cells were treated with
ethanol control or Bortezomib at 50nM for 16h. Cells were then trypsinized, collected,
stained with APC-Annexin V and PI, and analyzed by Flow Cytometry (Figure 3.4).
Bortezomib treatment leaded to a significant increase in apoptosis population only in cells
infected with BikDD lentivirus, not in the control group. To evaluate the impact difference
on apoptosis between infection and transfection, similar experiments were repeated by
Lipofectamine 2000 transfection. MDA-MB-231 cells were first transfected with vector or
BikDD plasmid, and then treated with 50nM Bortezomib for 16h before detection by flow
cytometry (Figure 3.5). Similar result came out as previous infection experiments. Cells
transfected with BikDD plasmid showed a higher apoptosis when under the treatment of
Bortezomib compared with control group. Cells transfected with BikDD had a statistically
significant increase in cell apoptosis compared with cells transfected with vector plasmid.
Cell apoptosis also increased when treated with Bortezomib in vector transfected cells.
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Figure 3.3 Bortezomib treatment enhances infected BikDD induced apoptosis in MDAMB-231 cell.
MDA-MB-231 cells were infected with lenti-virus containing vector or BikDD
DNA for 24h, and then treated with Bortezomib at 50nM for 16h. X axis: PI. Y axis: APCAnnexin V. A. Cells infected with vector lentivirus but without Annexin V/PI staining,
used as the technical control; B. Cells infected with vector, treated with ethanol control; C.
Cells infected with vector, treated with 50nM Bortezomib; D. Cells infected with BikDD,
treated with ethanol control; E. Cells infected with BikDD, treated with 50nM Bortezomib;
F. Bar diagram for B-E groups cell percentage with APC-Annexin V positive or PI positive
staining, indicating cell population undergo apoptosis. Statistical analysis was carried out
using Student's t test and data are shown as mean ± SD, n=3, *** indicates P<0.0001.
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Figure 3.4 Bortezomib treatment enhances BikDD apoptosis induction in MIA PaCa-2 cell.
MIA PaCa-2 cells were infected with lenti-virus containing vector or BikDD
DNA for 24h, and then treated with 50nM Bortezomib for 16h. X axis: PI. Y axis: APCAnnexin V. A. Cells infected with vector lentivirus but without Annexin V/PI staining,
used as the technical control; B. Cells infected with vector, treated with ethanol control; C.
Cells infected with vector, treated with 50nM Bortezomib; D. Cells infected with BikDD,
treated with ethanol control; E. Cells infected with BikDD, treated with 50nM Bortezomib;
F. Bar diagram for B,C,D,E groups cell percentage with APC-Annexin V positive or PI
positive staining, indicating cell population undergo apoptosis. Statistical analysis was
carried out using Student's t test and data are shown as mean ± SD, n=4, *** indicates
P<0.001.
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Figure 3.5 Bortezomib treatment enhances transfected BikDD apoptosis induction in
MDA-MB-231 cell.
MDA-MB-231 cells were transfected with vector or BikDD plasmid for 24h, and
then treated with ethanol or 50nM Bortezomib for 16h. Cells were then collected for flow
cytometry analysis by staining with APC-Annexin V and PI. X axis: PI. Y axis: APCAnnexin V. A. Cells transfected with vector DNA but without Annexin V/PI staining, used
as the technical control; B. Cells transfected with vector DNA, treated with ethanol control;
C. Cells transfected with vector DNA, treated with 50nM Bortezomib; D. Cells transfected
with BikDD DNA, treated with ethanol control; E. Cells transfected with vector DNA,
treated with 50nM Bortezomib; F. Bar diagram for B,C,D,E groups cell percentage with
APC-Annexin V positive or PI positive staining, indicating cell population undergo
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apoptosis. Statistical analysis was carried out using Student's t test and data are shown as
mean ± SD, n=4, ** indicates P<0.01, *** indicates P<0.001.

To test if the enhanced killing effect of BikDD when combined with proteasome
inhibitor came from accumulation of BikDD protein, we used siRNA to transiently knock
down Bik mRNA as well as BikDD mRNA after infection of BikDD lentivirus. siRNA
transfection was done by electroporation, and the knockdown efficacy was verified by
Western Blot after 24h. Cells were then treated with DMSO or 2µM MG132 for 16h before
fixed and stained by crystal violet for cell density determination (Figure 3.6). Due to the
damage caused by electroporation, about 50% MDA-MB-231 vector cells survived after
transfection in all groups with siRNA transfection including scramble siRNA group. In
BikDD cells, only about 5% cells survived after treatment with MG132 compared with
DMSO control group. Scramble siRNA transfection could not rescue cell survival, but Bik
siRNA transfection rescued cell survival back to around 20% to 30%. These results
indicated the enhanced killing effect when combining BikDD transfection and proteasome
inhibitor was at least partially contributed by accumulation of BikDD protein.

41

Figure 3.6 Accumulation of BikDD was responsible for enhanced killing effect induced by
proteasome inhibitor.
A. MDA-MB-231 cells infected with vector or BikDD lentivirus followed by
Bik siRNA electroporation to knock down the expression of BikDD. Sample 1-4 were
verification of siRNA knocking down efficiency 24h after electroporation; 48h after
electroporation, cells were treated with DMSO or 2µM MG132 for 16h, and sample 5-12
were the BikDD protein level in corresponding group. B. Bar diagram for cell density after
treated with MG132. Cell density was normalized to control group without treatment of
MG132. Statistical analysis was carried out using Student's t test and data are shown as
mean ± SD, n=3, * indicates P<0.05, ** indicates P<0.01, *** indicates P<0.001.
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3.3 Constant Low Level of BikDD Expression Provides Resistance to
BikDD Transfection
Proteasome degradation contributes to diminished apoptosis induction effect of
BikDD transfection, thus might functions as a potential resistance mechanism for BikDD
gene therapy. When put under constant pressure from low level of BikDD expression, cells
obtained a certain level of resistance against further BikDD transfection (Figure 3.7).
MDA-MB-231 cells were infected with vector or BikDD lentivirus, and maintained with
puromycin selection. MTT assay was carried out to determine the proliferation rate of these
two stable cell lines, and the result showed no significant difference (Figure 3.7). Different
dosages of BikDD plasmid were transfected into MDA-MB-231 vector cells and BikDD
expression cells. 1µg luciferase plasmid was co-transfected as marker for transfection
efficacy and cell viability. Luciferase assay was done to measure the killing effect of
BikDD transfection. At high dosage of BikDD plasmid transfection (1µg), most cells were
killed in both groups of vector cell line and BikDD cell line. At lower dosage of BikDD
plasmid transfection (0.25µg and 0.5µg), same dosage of BikDD plasmid transfection
produced lower killing effect in BikDD cell line group compared with vector cell line
group. These results indicated MDA-MB-231 cells with constant low level of BikDD
expression were less sensitive to BikDD gene therapy. For these cells, similar to previous
results, proteasome inhibitor treatment could significantly stabilize BikDD protein and
enhance cell apoptosis.
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Figure 3.7 MDA-MB-231 cells with constant low level of BikDD expression are less
sensitive to BikDD transfection.
MDA-MB-231 cells are infected with vector or BikDD lentivirus, selected and
maintained with puromycin. A. Cell proliferation measured by MTT assay. B. Stable cell
lines are then transfected with vector plasmid or different dosage of BikDD plasmids. X
axis: dosage of BikDD plasmid for transfection; Y axis: percentage of cells killed by
BikDD transfection, data normalized to control group without BikDD transfection.
Statistical analysis was carried out using Student's t test and data are shown as mean ± SD,
n=4, * indicates P<0.05, *** indicates P<0.001.
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3.4 BikDD Degradation is through Both Ubiquitylation Dependent and
Independent Pathways
Protein degraded through proteasome can happen through two different
pathways, ubiquitylation dependent pathway and ubiquitylation independent pathway. To
test which pathway mediated BikDD degradation, lysine sites on BikDD were mutated into
arginine to block possible ubiquitylation. BikDD is a small protein consists of 160 amino
acids, including only two lysines on site 115 and site 160 respectively. Single mutation and
double mutations were made on BikDD plasmid. N-termial ubiquitylation had also been
reported contributing to protein degradation, thus BikDD fused with mCherry tag on its Nterminal end was also constructed. Measurement of different mutated BikDD proteins halflife was exerted by adding cycloheximide to block protein synthesis, and detected BikDD
protein level up to 8 hours. Experiment result showed mutations on lysine sites did not
significant prolong the half-life of BikDD protein. However, when combined with Nterminal ubiquitylation blockage, BikDD protein became significantly more stable (Figure
3.8).
These result indicated ubiquitylation mediated pathway contributed to BikDD
degradation, and blockage of N-terminal ubiquitylation was essential for blocking its
degradation.
In the other way, when infected these different mutated BikDD into MDA-MB231 cells, proteasome inhibitor treatment still accumulated BikDD protein (Figure 3.8),
indicating the involvement of ubiquitylation independent pathway in its degradation.
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Figure 3.8 BikDD degradation happens through both ubiquitylation dependent and
independent pathway.
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Figure 3.9 BikDD degradation happens through both ubiquitylation dependent and
independent pathway.
Lysine mutations and N-terminal tag fusion are made on BikDD construct to
block possible ubiquitylation sites. A. Protein half-life of different mutant proteins.
Constructs containing different mutations of BikDD gene are infected in MDA-MB-231
cells, selected and maintained with purocymin. Cells are treated with 50µg/ml
Cycloheximide, and collected for WB analysis at different time points as indicated. B.
MDA-MB-231 cell with stable Flag-BikDD expression was treated with control DMSO or
10µM MG132 for 8h, collected with stringent lysis buffer and Flag antibody was used for
immunoprecipitation. WB was done with ubiquitin antibody. C. Effect of proteasome
inhibitor on protein accumulation in different mutants. MDA-MB-231 cells expressing
different mutated BikDD are treated with 10µM MG132 for 8h. Cell lysates are collected
for testing by WB. DPM: K115,K160 double point mutation into Arginine.
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3.5 Identification of E3 Ligase Responsible for BikDD Degradation
Due to the involvement of ubiquitylation dependent pathway in BikDD
degradation, we tried to identify the possible E3 ligase responsible for BikDD degradation
by treating Flag-BikDD stably expressed MDA-MB-231 cells with or without MG132,
immunoprecipitated BikDD protein by Flag tag recognition, verified by gel electrophoresis
silver staining and western blot against Bik, and used Mass Spectrum to identify the
binding proteins which associated with Flag-BikDD protein under different conditions.
MG132 inhibited proteasome function, thus supposed to pause BikDD protein degradation
processing and made BikDD protein stuck with E3 ligase and E2 enzyme.
Mass Spectrum analysis identified 168 proteins specifically bound with BikDD
under the treatment with MG132, but not without MG132 treatment; 460 proteins with
higher than 2 folds binding amount in MG132 treatment group compared with DMSO
control group. Among these proteins, there are 4 ubiquitin E3 ligases had been identified,
including AMFR, WWP2, HECTD1, and HUWE1. WWP2 was co-transfected into 293T
cells with BikDD, and didn’t show an effect in decreasing BikDD level (Figure 3.9).
shRNA targeting AMFR, HECTD1 and HUWE1 were used to knock down each of their
expression in MDA-MB-231 BikDD stably expression cells. Results showed knocking
down of these candidates could not rescue the basal level of BikDD expression, and BikDD
still accumulated after treatment with MG132 (Figure 3.9).
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Figure 3.10 Identification and verification of effect of E3 ligase candidates.
MDA-MB-231 cells with stable expression of Flag-BikDD were treated with
DMSO control or 10µM MG132 for 8h. Flag-BikDD was then immunoprecipitated by Flag
antibody, and its binding proteins were eluted and prepared for Mass Spectrum. Western
blot (A) and silver staining (B) were used to verify the protein samples. C. WWP2 is cotransfected into 293T cells with BikDD to verify its effect in facilitating BikDD
degradation. Number indicates WWP2 DNA ratio to BikDD. D. shRNA targeting AMFR,
HECTD1, HUWE1 are used to silence the expression of respective protein in BikDD
expressed MDA-MB-231 cells. Cells are then treated with DMSO or 10µM MG132 for 8h,
and protein level of BikDD are detected by WB.
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3.6 Induction of BikDD Specific Monoclonal Antibody
Due to potential application in clinical trial, we developed monoclonal antibody
specifically recognizing BikDD other than Bik protein. Peptide for antibody induction was
designed around the specific mutations T33D and S35D. Peptide sequence for induction is
MDDDEEDLDPC; peptide sequence for control is MTDSEEDLDPC. 39 mice were
immunized with specific peptide, and one of the mice produced polyclonal antibody with
preference in recognizing BikDD protein over Bik protein. Plasma cells were taken from
the positive mice, and fused with myeloma cells to produce hybridomas secreting
monoclonal antibody. After 4 rounds of subcloning, one strains were selected, purified and
named 9A2.8.
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Figure 3.11 Induction of BikDD specific monoclonal antibody.
Protein samples come from 293T cells transfected with Vector/ Flag-Bik/ BikDD
plasmids. BikDD was loading at different concentrations. Lane 1: Vector Control; Lane 2:
Flag-Bik; Lane 3: BikDD (1*Concentration); Lane 4: BikDD (2*Concentration); Lane 5:
BikDD (4*Concentration); Lane 6: BikDD (16*Concentration). A. Proteins were detected
by polyclonal Bik antibody (Cell signalling #4592) which recognizes Bik and BikDD
proteins with similar capability. B. Proteins were detected by monoclonal BikDD antibody,
which shows a preference in recognizing BikDD protein over Bik protein.
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Chapter 4 . Discussion
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Our results indicate proteasome degradation contributes to a reduced level of
BikDD expression and a reduced effect on cell apoptosis induction by BikDD. In our study,
every cell line we tested possesses the ability to degrade exogenously expressed BikDD.
According to published studies, some types of cancer, including basal like triple negative
breast cancer, are addictive to proteasome [160]. Based on these facts, proteasome inhibitor
could be applied to generally stabilize the protein level of transfected BikDD and enhance
its apoptosis induction effect. Meanwhile, proteasome degradation could function as a
potential mechanism for resistance in BikDD gene therapy. Cancer cell is a heterogeneous
population, and cells with higher proteasome activity would be able to degrade the
exogenous BikDD to an acceptable level, thus with intrinsic resistance to gene therapy. For
some cancer cell population, their proteasome activity might be activated after several
rounds of therapy. In this case, proteasome degradation functions as the acquired resistance
mechanism. For these resistant cancer cells, proteasome inhibitors could also be applied as
a combinational strategy with BikDD gene therapy to block protein degradation and
sensitize cancer cells to BikDD gene therapy.
Multiple proteasome inhibitors have been approved for clinical therapy or under
clinical trials. If combined with BikDD gene therapy which specifically expresses proapoptotic protein BikDD in targeting cancer cells, dosage for applied proteasome inhibitor
might be reduced to minimize the side effect on normal cells. In our results, we only tested
the effect of combining proteasome inhibitor and BikDD transfection in in vitro system. To
further confirm the efficacy and feasibility of combination therapy, in vivo experiments in
mouse model will be needed.
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We treated different cancer cells with proteasome inhibitor Bortezomib
combined with BikDD transfection/infection, and the killing effects were measured by
Annexin V/PI staining. Annexin V is an apoptosis specific marker by recognizing PS
which locates in the inner cell membrane under normal cell condition, but translocates to
the extracellular membrane during apoptosis process. PI functions based on the cell
membrane permeability change. During the early stages of apoptosis, cell membrane
excludes the permeation of PI, thus Annexin V positive but PI negative indicates the early
apoptosis population. Late stages of apoptosis when PI can penetrate cell membrane are
then indicated by Annexin V positive and PI positive staining. However, PI is not an
apoptosis specific marker due to the mechanism of its function. It also stains cell undergo
necrosis and other types of cell death as long as the cell membrane permeability changes.
In our result section, we quantitated all three populations (Annexin V positive, PI negative;
Annexin V positive, PI positive; Annexin V negative, PI positive) to evaluate the total
cancer cell killing effect of combined therapy. If considering the specific function of
BikDD, Annexin V only could be used as a more specific indicator for analyzing the
apoptosis induction function of combined therapy (Figure 4.1). Due to the limited
population of Annexin V negative but PI positive cell, apoptosis induction effect of
combined therapy is not quantitatively different from total cell death induction effect.
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Figure 4.1 Apoptosis induction effect of combined proteasome inhibitor treatment and
BikDD gene therapy.
Experiments in Figure 3.3 (A, BikDD transfection in MDA-MB-231 cell), Figure
3.4 (B, BikDD infection in MDA-MB-231 cell) and Figure 3.5 (C, BikDD infection in
MIA-PaCa2 cell) were re-analyzed. Apoptosis cell percentage was measured as Annexin V
positive population.

To further reduce the side effect of applying proteasome inhibitor, we
investigated detailed mechanism mediating BikDD degradation. Based on results from the
current study, ubiquitylation dependent and independent proteasome degradation pathway
both contribute to BikDD degradation, and ubiquitylation could happen on multiple sites.
These results imply the precise regulation of BikDD protein level in cancer cells, and
similar multiple pathways regulation should also be applied in endogenous Bik and other
pro-apoptotic and anti-apoptotic proteins. Verification of the four E3 ligase candidates
from mass spectrum database did not figure out one with significant effect on mediating
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BikDD degradation. However, it does not reduce the possible contribution from
ubiquitylation dependent pathway. The mass spectrum analysis used in this project is for
protein identification, but not quantitation. Advanced quantitation mass spectrum might be
more helpful for analyzing the amount of binding proteins with BikDD. Further
investigations could focus on other proteasome degradation related proteins, and knocking
down different E3 ligases simultaneously since BikDD might be tightly regulated under
multiple regulators in cancer cells for escaping apoptosis. Previous studies have indicated
ubiquitylation not on N-terminal could happen on non-lysine residues [93-95]. Thus,
possibilities of ubiquitylation on other amino acids except lysine on BikDD should not be
excluded. Meanwhile, other modifications might also contribute to protein degradation.
One of the possible examples is sumoylation, especially RanBP2, a SUMO E3 ligase is
identified in our mass spectrum database only binding to BikDD under the condition of
proteasome inhibitor treatment. Mass spectrum to identify post-translational modifications
on BikDD protein might be helpful to analyze the possibility of ubiquitylation happen on
non-classical lysine residue, and provide information of other post-translational
modification.
Identification of specific regulators, such as E3 ligases, for BikDD stability
might provide alternative combinational strategy with fewer side effects compared with
general proteasome inhibition if they are targetable. These regulators might also function as
prediction markers to help predict patients response for BikDD gene therapy, thus help
select appropriate patients for therapy. However, regulators for BikDD degradation in
different tumor types and subtypes might be different, thus more efforts would be needed.
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In our study, siRNA targeting Bik as well as BikDD mRNA was used to verify
the enhanced apoptosis effect by proteasome inhibitor treatment was contributed by BikDD
accumulation. siRNA knocking down BikDD rescued cell survival from 10% to 50% when
normalized to cells without previous BikDD infection, indicating the major contribution of
BikDD accumulation in enhanced apoptosis. However, siRNA knockdown could not
rescue cell survival back to 100%. One explanation is the siRNA knocking down efficacy
in BikDD lentivirus previous infected cells was not good enough. Especially when treated
with proteasome inhibitor, there is still a detectable level of BikDD expression compared
with undetectable level in vector lentivirus infected cells. The existence of BikDD might
contribute to the apoptosis which cannot be rescued. Another possibility for this
phenomenon is BikDD lentivirus infected cells are more sensitive to electroporation and
other damage, thus leading to a lower survival percentage.
Another possible reason that cannot be neglected is induction of other variations
in cells caused by expression of BikDD protein. When BikDD is overexpressed in cells,
even in a minimal level, some apoptosis related proteins would be regulated to adapt the
increase of a pro-apoptosis protein. When BikDD expression level is within the acceptable
range, some anti-apoptosis proteins might be up-regulated and some other pro-apoptotic
proteins might be down-regulated to maintain cell survival. These regulations could happen
on both transcription and translation levels, and proteasome inhibition might restore other
pro-apoptotic proteins which cannot be rescued by siRNA targeting BikDD. Other
variations not limited to apoptotic related proteins caused by BikDD expression also
possibly exist.
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Wang, Y. et al previously reported the serine protease RHBDD1 cleaved Bik on
its C-terminal, and contributed to its degradation [120], so the contribution of RHBDD1
mediated BikDD degradation should also be considered. In our results, stabilization of
BikDD protein was mediated by treatment of MG132 or Bortezomib, whose effects were
specifically carried out through targeting proteasome. Protein catalytic sites in proteasome
majorly utilize the threonine residue N-terminal hydroxyl group, and classified as the
threonine protease group, which is different from serine proteases in catalyzing protein
degradation. Indeed, the lack of serine protease and cysteine protease activity in
proteasome facilitates the development of its specific drugs. Thus the effect of BikDD
protein accumulation caused by MG132 and Bortezomib is unlikely mediated through the
activity of RHBDD1, although RHBDD1 might possess additional effect in degrading
BikDD. Furthermore, RHBDD1 is a non-targetable serine protease according to current
protease inhibitor database, thus with a less value in clinical application.
BikDD specific monoclonal antibody was developed to benefit future clinical
test, and showed a high preference on recognizing BikDD protein over Bik protein by
Western blot test. Due to the extremely low level of endogenous Bik protein expression
even with treatment of proteasome inhibitor, we didn’t use the specific BikDD antibody in
our current study, but it should be required in clinical test. For possible clinical application,
the monoclonal antibody specificity should be further tested in immunohistochemistry
staining and on tissue sample.
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